Trial Profile

AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF-08046037 (Primary) ; Sasanlimab (Primary)
Indications Adenocarcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

12 Jun 2025 Planned End Date changed from 28 Feb 2029 to 27 Jul 2029.
12 Jun 2025 Planned primary completion date changed from 29 Feb 2028 to 27 Jul 2028.
12 Jun 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com